Basic scienceUpregulation of prostate-specific membrane antigen after androgen-deprivation therapy*
References (36)
- et al.
Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies
J Urol
(1960) Endocrine therapy for prostate cancer
Endocrinol Metab Clin North Am
(1991)- et al.
Expression of prostate-specific membrane antigen in normal, benign and malignant prostate tissues
Urol Oncol
(1995) - et al.
Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356
J Urol
(1994) - et al.
Radioimmunoscintigraphy with 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence
J Urol
(1994) - et al.
Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients
J Urol
(1989) - et al.
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
J Urol
(1992) - et al.
Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer
J Urol
(1995) - et al.
Hormone regulation of transforming growth factor beta-2 expression in human prostate cancer
J Steroid Biochem
(1993) - et al.
Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
Blood
(1993)
Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformai radiation therapy
Int J Radiat Oncol Biol Phys
(1994)
Chemotherapy for prostatic carcinoma
Semin Urol
(1988)
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
Cancer
(1993)
Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy
Prostate
(1985)
Pathologic changes associated with androgen deprivation therapy for prostate cancer
Cancer
(1991)
Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients
Anticancer Res
(1987)
Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT356)
Prostate
(1991)
Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer
Semin Urol
(1992)
Cited by (0)
- *
This study was supported in part by a grant from the Cytogen Corporation, Princeton, New Jersey.
Copyright © 1996 Published by Elsevier Inc.